Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

The current study evaluated amyloid-β oligomers (Aβo) in cerebrospinal fluid as a clinical biomarker for Alzheimer's disease (AD). We developed a highly sensitive Aβo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detection. CSF samples from patients with AD, mild co...

Full description

Bibliographic Details
Main Authors: Mikko Hölttä, Oskar Hansson, Ulf Andreasson, Joakim Hertze, Lennart Minthon, Katarina Nägga, Niels Andreasen, Henrik Zetterberg, Kaj Blennow
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3682966?pdf=render

Internet

http://europepmc.org/articles/PMC3682966?pdf=render

Similar Items